Table 6.
Study data sources.
| Phenotypes: | Consortium | First author (Year) | Sample size | N cases | N controls | Population |
|---|---|---|---|---|---|---|
| Exposures: | ||||||
| Drinks per week | GSCAN | Liu (2019) | 941,280 | NA | NA | European |
| Alcohol use disorder | PGC | Walters (2019) | 28,757 | 8485 | 20,272 | European |
| Lifetime smoking | MRC-IEU | Wootton (2019) | 462,690 | NA | NA | European |
| Cannabis Use | PGC | Pasman (2018) | 162,082 | 43,380 | 118,702 | European |
| Cannabis Use Disorder | PGC | Johnson (2020) | 358,534 | 14,808 | 343,726 | European |
| Coronary Artery Disease | CARDIoGRAMplusC4D | van der Harst (2017) | 547,261 | 122,733 | 424,528 | European |
| Type 2 Diabetes | DIAGRAM | Xue (2018) | 590,283 | 50,721 | 539,562 | European |
| Obesity Class I | GIANT | Berndt (2013) | 98,697 | 32,858 | 65,839 | European |
| Obesity Class II | GIANT | Berndt (2013) | 725,46 | 9889 | 62,657 | European |
| Obesity Class III | GIANT | Berndt (2013) | 50,364 | 2896 | 47,468 | European |
| COVID-19 outcomes (Round 5): | ||||||
| Very severe respiratory confirmed COVID-19 vs. population | COVID 19-hg | — | 707,407 | 4606 | 702,801 | European |
| Very severe respiratory confirmed COVID-19 vs. population (excluding UKB) | COVID 19-hg | — | 378,521 | 4297 | 374,224 | European |
| Hospitalized vs. not hospitalized COVID-19 | COVID 19-hg | — | 16,645 | 4829 | 11,816 | European |
| Hospitalized vs. not hospitalized COVID-19 (excluding UKB) | COVID 19-hg | — | 10,365 | 3159 | 7,206 | European |
| Hospitalized COVID-19 vs. population | COVID 19-hg | — | 1,206,629 | 9373 | 1,197,256 | European |
| Hospitalized COVID-19 vs. population (excluding UKB) | COVID 19-hg | — | 876,382 | 7703 | 868,679 | European |
| COVID-19 vs. population | COVID 19-hg | — | 1,588,783 | 29,071 | 1,559,712 | European |
| COVID-19 vs. population (excluding UKB) | COVID 19-hg | — | 1,25,3716 | 22,581 | 1,231,135 | European |
| FinnGen outcomes (Release 5): | ||||||
| Acute Upper Respiratory Infections | FinnGen | — | 218,792 | 35,847 | 182,945 | European |
| Asthma related acute respiratory infections | FinnGen | — | 142,793 | 7348 | 135,445 | European |
| Asthma/COPD (Kela code 203) | FinnGen | — | 208,167 | 21,444 | 186,723 | European |
| Asthma related infections | FinnGen | — | 218,792 | 58,925 | 159,867 | European |
| Asthma-related pneumonia or sepsis | FinnGen | — | 140,994 | 5545 | 135,449 | European |
| Asthma-related pneumonia | FinnGen | — | 140,981 | 5532 | 135,449 | European |
| Bacterial pneumonia | FinnGen | — | 196,855 | 7987 | 188,868 | European |
| Bronchitis | FinnGen | — | 218,792 | 27,361 | 191,431 | European |
| Chronic Lower Respiratory Diseases | FinnGen | — | 218,792 | 32,069 | 186,723 | European |
| Acute nasopharyngitis (common cold) | FinnGen | — | 185,198 | 2253 | 182,945 | European |
| Influenza | FinnGen | — | 193,130 | 4262 | 188,868 | European |
| Influenza and Pneumonia | FinnGen | — | 218,792 | 29,924 | 188,868 | European |
| All Pneumoniae | FinnGen | — | 218,798 | 27,376 | 191,422 | European |
| Viral Pneumonia | FinnGen | — | 189,568 | 700 | 188,868 | European |
GSCAN GWAS & Sequencing Consortium of Alcohol and Nicotine, MRC-IEU Medical Research Council Integrative Epidemiology Unit, PGC Psychiatric Genomics Consortium, GIANT Genetic Investigation of ANthropometric Traits, CARDIoGRAMplusC4D Coronary ARtery DIsease Genome-wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) Genetics), DIAGRAM DIAbetes Genetics Replication and Meta-analysis, COVID-19 coronavirus disease 2019.